# Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis

> **NCT02566044** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Pulmonary Cystic Fibrosis

## Interventions

- **OTHER:** Placebo
- **DRUG:** QBW276

## Key facts

- **NCT ID:** NCT02566044
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-27
- **Primary completion:** 2018-04-24
- **Final completion:** 2018-04-24
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02566044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02566044, "Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02566044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*